RhumbLine Advisers
IMVT icon

RhumbLine Advisers’s Immunovant IMVT Stock Holding History

RhumbLine Advisers’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.65M Buy
108,185
+1,039
+1% +$40.9K ﹤0.01% 1590
2026
Q2 		$4.13M Buy
107,146
+9,653
+10% +$294K ﹤0.01% 1565
2026
Q1 		$2.42M Buy
97,493
+10,646
+12% +$276K ﹤0.01% 1753
2025
Q4 		$2.21M Sell
86,847
-12,126
-12% -$270K ﹤0.01% 1828
2025
Q3 		$1.6M Sell
98,973
-2,408
-2% -$39K ﹤0.01% 2024
2025
Q2 		$1.62M Buy
101,381
+17,826
+21% +$270K ﹤0.01% 1995
2025
Q1 		$1.43M Buy
83,555
+2,623
+3% +$54.9K ﹤0.01% 1989
2024
Q4 		$2M Buy
80,932
+1,188
+1% +$33.7K ﹤0.01% 1871
2024
Q3 		$2.27M Sell
79,744
-3,788
-5% -$112K ﹤0.01% 1833
2024
Q2 		$2.21M Buy
83,532
+7,363
+10% +$209K ﹤0.01% 1833
2024
Q1 		$2.46M Buy
76,169
+1,810
+2% +$66K ﹤0.01% 1799
2023
Q4 		$3.13M Sell
74,359
-206
-0.3% -$7.58K ﹤0.01% 1675
2023
Q3 		$2.86M Buy
74,565
+2,367
+3% +$53.5K ﹤0.01% 1666
2023
Q2 		$1.37M Buy
72,198
+550
+0.8% +$10.3K ﹤0.01% 2130
2023
Q1 		$1.11M Buy
71,648
+1,806
+3% +$31.3K ﹤0.01% 2073
2022
Q4 		$1.24M Buy
69,842
+7,460
+12% +$93.9K ﹤0.01% 2026
2022
Q3 		$348K Buy
62,382
+4,207
+7% +$20.6K ﹤0.01% 2664
2022
Q2 		$227K Buy
58,175
+12,711
+28% +$54.9K ﹤0.01% 2882
2022
Q1 		$251K Sell
45,464
-25
-0.1% -$156 ﹤0.01% 2696
2021
Q4 		$388K Sell
45,489
-601
-1% -$4.96K ﹤0.01% 2617
2021
Q3 		$401K Buy
46,090
+1,880
+4% +$17K ﹤0.01% 2644
2021
Q2 		$467K Buy
44,210
+2,252
+5% +$31.4K ﹤0.01% 2594
2021
Q1 		$673K Sell
41,958
-1,755
-4% -$46.3K ﹤0.01% 2360
2020
Q4 		$2.02M Buy
43,713
+5,963
+16% +$276K ﹤0.01% 1838
2020
Q3 		$1.33M Buy
37,750
+14,849
+65% +$447K ﹤0.01% 1881
2020
Q2 		$558K Buy
+22,901
New +$491K ﹤0.01% 2294

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

RhumbLine Advisers's IMVT Position: Q3 2026 in Review

RhumbLine Advisers increased its Immunovant (IMVT) stake by 0.97% in Q3 2026, buying an estimated $40.9K and bringing the position to 108,185 shares worth $3.65M. The position accounts for ﹤0.01% of the portfolio, ranked #1590.

RhumbLine Advisers first reported a position in IMVT in Q2 2020 and has held it in 26 quarters since. The position peaked at $4.13M in Q2 2026. 160 funds tracked by Wall St. Rank hold IMVT as of Q3 2026.

  • RhumbLine Advisers held 108,185 shares of Immunovant worth $3.65M as of Q3 2026.
  • RhumbLine Advisers bought 1,039 Immunovant shares in Q3 2026, an estimated $40.9K.
  • Immunovant made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #1590 holding.
  • RhumbLine Advisers first reported a position in Immunovant in Q2 2020 and has held it in 26 quarters since.
  • RhumbLine Advisers's Immunovant position peaked at $4.13M in Q2 2026.
  • 160 funds tracked by Wall St. Rank held Immunovant as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.